<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Nevada National Board Professional Learning Institute | Dalsgaard | Activity</title>
	<link>http://www.nationalboardinstitute.com/members/ordertemple08/activity/</link>
	<atom:link href="http://www.nationalboardinstitute.com/members/ordertemple08/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Dalsgaard.</description>
	<lastBuildDate>Fri, 23 May 2025 17:06:54 -0700</lastBuildDate>
	<generator>https://buddypress.org/?v=9.1.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">8d75e9f63c0c53878f49226bee88c429</guid>
				<title>Dalsgaard posted an update: Antisense oligonucleotide (ASO)-based therapy is one of the [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/41211/</link>
				<pubDate>Fri, 07 Feb 2025 11:50:43 -0800</pubDate>

									<content:encoded><![CDATA[<p>Antisense oligonucleotide (ASO)-based therapy is one of the next-generation therapy, especially targeting neurological disorders. Many cases of ASO-dependent gene expression suppression have been reported. Recently, we developed a tocopherol conjugated DNA/RNA heteroduplex oligonucleotide (Toc-HDO) as a new type of drug. Toc-HDO is more potent,&hellip;<span class="activity-read-more" id="activity-read-more-41211"><a href="http://www.nationalboardinstitute.com/activity/p/41211/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">c7de3b4df35396e7c33361063919f803</guid>
				<title>Dalsgaard posted an update: However, their final height was not compromised when [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/37622/</link>
				<pubDate>Mon, 03 Feb 2025 11:36:49 -0800</pubDate>

									<content:encoded><![CDATA[<p>However, their final height was not compromised when compared to their family height target. We found pubertal delay in 12%; accelerated/precocious puberty in 13.2%; central and primary hypogonadism in 21.9% and 3.3%, respectively; primary and central hypothyroidism in 23.6% and 14.5%, respectively; thyroid nodules in 7.4%; ACTH deficiency in&hellip;<span class="activity-read-more" id="activity-read-more-37622"><a href="http://www.nationalboardinstitute.com/activity/p/37622/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">337e338167350dae103311145a850860</guid>
				<title>Dalsgaard posted an update: CD19 is among the most relevant targets in cancer [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/36702/</link>
				<pubDate>Sun, 02 Feb 2025 11:42:47 -0800</pubDate>

									<content:encoded><![CDATA[<p>CD19 is among the most relevant targets in cancer immunotherapy. However, its extracellular domain (ECD) is prone to aggregation and misfolding, representing a major obstacle for the development and analysis of CD19-targeted therapeutics. Here, we engineered stabilized CD19-ECD (termed SuperFolder) variants, which also showed improved expression&hellip;<span class="activity-read-more" id="activity-read-more-36702"><a href="http://www.nationalboardinstitute.com/activity/p/36702/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">70a4d2c470490304ddb9adad6e50713d</guid>
				<title>Dalsgaard posted an update: Understanding the history of the Greenland Ice Sheet (GrIS) [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/35855/</link>
				<pubDate>Sat, 01 Feb 2025 11:38:22 -0800</pubDate>

									<content:encoded><![CDATA[<p>Understanding the history of the Greenland Ice Sheet (GrIS) is critical for determining its sensitivity to warming and contribution to sea level; however, that history is poorly known before the last interglacial. Most knowledge comes from interpretation of marine sediment, an indirect record of past ice-sheet extent and behavior. Subglacial&hellip;<span class="activity-read-more" id="activity-read-more-35855"><a href="http://www.nationalboardinstitute.com/activity/p/35855/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">504b043b292c4fc8a1144e37f2e5507a</guid>
				<title>Dalsgaard posted an update: vitamin D for osteomalacia and anti-osteoporotic [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/34104/</link>
				<pubDate>Thu, 30 Jan 2025 11:48:43 -0800</pubDate>

									<content:encoded><![CDATA[<p>vitamin D for osteomalacia and anti-osteoporotic osteoporosis regimens will hopefully enhance bone, muscle, and general health, minimizing falls and fractures.Background and aim Gram-negative rods (GNR) are the most common pathogens associated with urinary tract infections (UTI). The resistance of these gram-negative rods to various antibiotics is&hellip;<span class="activity-read-more" id="activity-read-more-34104"><a href="http://www.nationalboardinstitute.com/activity/p/34104/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">a6a36df57debe60297520b7fecc775f3</guid>
				<title>Dalsgaard became a registered member</title>
				<link>http://www.nationalboardinstitute.com/activity/p/30784/</link>
				<pubDate>Tue, 28 Jan 2025 15:43:02 -0800</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>